Mirati Therapeutics (MRTX) Getting Somewhat Favorable Media Coverage, Study Finds
Press coverage about Mirati Therapeutics (NASDAQ:MRTX) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mirati Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.537212451614 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Mirati Therapeutics, Inc. (MRTX) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- New Research: Key Drivers of Growth for Express Scripts Holding, D.R. Horton, Mirati Therapeutics, EchoStar, Toro, and Genesee & Wyoming — Factors of Influence, Major Initiatives and Sustained Product (markets.financialcontent.com)
- Zacks: Analysts Expect Mirati Therapeutics, Inc. (MRTX) to Announce -$0.65 Earnings Per Share (americanbankingnews.com)
- Mirati Therapeutics (MRTX) Cut to “Sell” at ValuEngine (americanbankingnews.com)
- Contrasting Mirati Therapeutics (MRTX) and Mateon Therapeutics (MATN) (americanbankingnews.com)
Mirati Therapeutics (MRTX) opened at $16.15 on Friday. Mirati Therapeutics has a 52-week low of $2.70 and a 52-week high of $19.25.
Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.16. sell-side analysts expect that Mirati Therapeutics will post -2.77 EPS for the current year.
MRTX has been the topic of a number of recent analyst reports. ValuEngine raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 16th. Oppenheimer reaffirmed a “buy” rating and set a $18.00 target price on shares of Mirati Therapeutics in a research report on Wednesday, November 22nd. Leerink Swann raised Mirati Therapeutics from a “market perform” rating to an “outperform” rating and set a $9.00 target price on the stock in a research report on Tuesday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price (down from $20.00) on shares of Mirati Therapeutics in a research report on Tuesday, November 14th. Finally, Zacks Investment Research lowered Mirati Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. Mirati Therapeutics presently has a consensus rating of “Buy” and an average price target of $13.71.
In other Mirati Therapeutics news, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were purchased at an average cost of $13.00 per share, with a total value of $8,450,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jamie Christensen sold 7,499 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $14.00, for a total value of $104,986.00. Following the transaction, the senior vice president now directly owns 10,169 shares in the company, valued at $142,366. The disclosure for this sale can be found here. Insiders have sold 23,544 shares of company stock worth $365,826 over the last three months. 5.10% of the stock is owned by insiders.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.